Legal Opinion
In Re: Biogen Inc. Sec. Litig. v.
Court of Appeals for the First Circuit
Decided May 12, 2017No. 16-1976PPublishedCited by 41 opinions
1Opinion of the Court
LYNCH, Circuit Judge.
This securities case involves allegations that corporate officials misled the public about the effect of one patient’s death on sales of Tecfidera, a drug for multiple sclerosis (“MS”) and the company’s leading source of revenue.
GBR Group, Ltd. (“GBR”) is the lead plaintiff in a putative class action against Biogen Inc. (“Biogen”) and three Biogen executives (together, “the defendants”) alleging violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). See 15 U.S.C. §§ 78j(b), 78t(a). The plaintiffs’ initial amended complaint…
2Cases cited17 opinions
- Tellabs, Inc. v. Makor Issues & Rights, Ltd.Supreme Court of the United States · 2007
- Ernst & Ernst v. HochfelderSupreme Court of the United States · 1976
- Greebel v. FTP Software, Inc.Court of Appeals for the First Circuit · 1999
- Ruiz Rivera v. PEIZER PHARMACEUTICALS, LLCCourt of Appeals for the First Circuit · 2008
- Mesko v. Cabletron System, Inc.Court of Appeals for the First Circuit · 2002
12 more not listed; retrieve them via the Exa API.
3Cited by41 opinions
- LifeWise Family Financial v. Triangle Capital CorporationCourt of Appeals for the Fourth Circuit · 2021
- Ponsa-Rabell v. Santander Securities, LLCCourt of Appeals for the First Circuit · 2022
- Metzler Asset Mgmt. GMBH v. KingsleyCourt of Appeals for the First Circuit · 2019
- United States Ex Rel. Nargol v. Depuy Orthopaedics, Inc.Court of Appeals for the First Circuit · 2017
- Constr. Industry and Laborers Joint Pension Trust v. Carbonite, Inc.Court of Appeals for the First Circuit · 2021
36 more not listed; retrieve them via the Exa API.